Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.
Amgen's Capital Expenditure for the
three
months ended in Jun. 2023 was $-271.00 Mil. Its Operating Income for the
three
months ended in Jun. 2023 was $2,684.00 Mil.
Hence, Amgen's Capex-to-Operating-Income for the
three
months ended in Jun. 2023 was 0.10.
Amgen Capex-to-Operating-Income Historical Data
The historical data trend for Amgen's Capex-to-Operating-Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Amgen Annual Data
Trend
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Capex-to-Operating-Income
0.07
0.06
0.07
0.10
0.10
Amgen Quarterly Data
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Capex-to-Operating-Income
0.11
0.06
0.15
0.18
0.10
Competitive Comparison
For the Drug Manufacturers - General subindustry, Amgen's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen Capex-to-Operating-Income Distribution
For the Drug Manufacturers industry and Healthcare sector, Amgen's Capex-to-Operating-Income distribution charts can be found below:
* The bar in red indicates where Amgen's Capex-to-Operating-Income falls in comparison to its industry or sector. The grey bar indicates the Capex-to-Operating-Income's extreme value range as defined by GuruFocus.
Amgen Capex-to-Operating-Income Calculation
Amgen's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.
Amgen Capex-to-Operating-Income Related Terms
Thank you for viewing the detailed overview of Amgen's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amjevita (biosimilar Humira).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
0.84(0.31%) Volume: 1,670,988 11:08PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
AMGN has been successfully added to your 
